Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of abicipar versus ranibizumab in treatment-naive neovascular age-related macular degeneration
NL-OMON43671Phase 3Active, not recruiting
- Sponsor
- Allergan
- Start
- Apr 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abicipar pegol and ranibizumab in exudative macular degeneration, sponsored by Allergan. Primary endpoint: Percentage of patients with BCVA change from baseline of at least 15 letters at week 52. Started Apr 2016; status: active, not recruiting.
02
Drugs
abicipar pegolranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON43671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43671.